1887

Journal of General Virology header logo

Volume 77, Issue 12

Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1 Free

Abstract

Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of human immunodeficiency virus type 1 (HIV-1) V3, and MAb F58 (mouse IgG1) recognizes the peptide IXXGPGR, at the tip of the V3 loop. Both MAbs neutralized HIV-1 strain IIIB in C8166 and HeLa-T4(CD4) cells. Neutralization by either MAb did not inhibit attachment of virus to target cells as determined by FACS analysis, ELISA or immuno-fluorescence, and such attachment was absolutely dependent on the availability of CD4 molecules. F58 inhibited virus-induced cell-cell fusion, and reduced internalization of virions in direct proportion to neutralization. In contrast, ICR41.1i had no effect on HIV-1-mediated cell fusion or on internalization of virus. It was concluded that MAb F58 neutralized infectivity by inhibiting fusion of the virus with the cell and internalization of the viral core, and that ICR41. 1i neutralized by inhibiting a post-fusion-internalization event. The possible mechanism by which a neutralizing antibody binds to the V3 loop and affects the function(s) of structures inside the virion is discussed. Lastly, post-attachment neutralization (PAN) was investigated. F58 mediated PAN at 21 °C and 35 °C. However, ICR41. 1i gave PAN at 21 °C but not at 35 °C, suggesting that a temperature-dependent event affecting the V3 loop had abrogated neutralization. Overall, it appears that antibodies to different epitopes within the V3 loop neutralize by affecting very different functions of the virus.

  • Received:
  • Accepted:
  • Published Online:
© Journal of General Virology 1996
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-77-12-2931
1996-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/77/12/JV0770122931.html?itemId=/content/journal/jgv/10.1099/0022-1317-77-12-2931&mimeType=html&fmt=ahah

References

  1. Åkerblom L., Hinkula J., Broliden P.-A., Makitalo B., Fridberger T., Rosen J., Villacres-Erikssen M., Morein B., Wahren B. 1990; Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 4:953–960
     [Google Scholar]
  2. Armstrong S. J., Dimmock N. J. 1992; Neutralization of influenza virus by low concentrations of HA-specific polymeric IgA inhibits viral fusion activity but activation of the ribonucleoprotein is also inhibited. Journal of Virology 66:3823–3832
     [Google Scholar]
  3. Armstrong S. J., Dimmock N. J. 1996; Varying temperature-dependence of post-attachment neutralization of human immunodeficiency virus type 1 by monoclonal antibodies to gp120: identification of a very early fusion-dependent event as a neutralization target. Journal of General Virology 77:1397–1402
     [Google Scholar]
  4. Back N. K. T., Smit L., Schutten M., Nara P. L., Tersmette M., Goudsmit J. 1993; Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. Journal of Virology 67:6897–6902
     [Google Scholar]
  5. Benjouad A., Chapuis F., Fenouillet E., Gluckman J.-C. 1995; Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gpl20 inhibit HIV-1 infection through interaction with CD4. Virology 206:457–464
     [Google Scholar]
  6. Bukrinsky M. I., Sharova N., McDonald T. L., Pushkarskaya T., Tarpley W. G., Stevenson M. 1993; Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proceedings of the National Academy of Sciences, USA 90:6125–6129
     [Google Scholar]
  7. Cavacini L. A., Ernes C. L., Power J., Duval M., Posner M. R. 1994; Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization. Journal of Immunology 152:2538–2545
     [Google Scholar]
  8. Clements G. J., Price-Jones M. J., Stephens P. E., Sutton C., Schultz T. F., Clapham P. R., McKeating J. A., McClure M. O., Thompson S., Marsh M., Kay J., Weiss R. A., Moore J. P. 1991; The V3 loops of HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion. AIDS Research and Human Retroviruses 7:3–16
     [Google Scholar]
  9. Dimmock N. J. 1993; Neutralization of animal viruses. Current Topics in Microbiology and Immunology 183:1–149
     [Google Scholar]
  10. Dimmock N. J. 1995; Update on the neutralization of animal viruses. Reviews in Medical Virology 5:165–179
     [Google Scholar]
  11. Freed E. O., Martin M. A. 1996; Domains on the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. Journal of Virology 70:341–351
     [Google Scholar]
  12. Freed E. O., Myers D. J., Risser R. 1991; Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. Journal of Virology 65:190–194
     [Google Scholar]
  13. Gallay P., Swingler S., Aiken C., Trono D. 1995; HIV-1 infection of non-dividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell 80:379–388
     [Google Scholar]
  14. Healy D., Dianda L., Moore J. P., McDougal J. S., Moore M. J., Estess P., Buck D., Kwong P. D., Beverley P. C. L., Sattentau Q. J. 1990; Novel anti-CD4 monoclonal antibodies separate HIV infection and fusion of CD4 + cells from virus binding. Journal of Experimental Medicine 172:1233–1242
     [Google Scholar]
  15. Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. 1988; Second conserved domain of gpl20 is important for HIV infectivity and antibody neutralization. Science 239:1021–1023
     [Google Scholar]
  16. Iorio R. M., Glickman R. L., Riel A. M., Sheehan J. P., Bratt M. A. 1989; Functional and neutralization profile of seven overlapping antigenic sites on the HN glycoprotein of Newcastle disease virus: monoclonal antibodies to some sites prevent attachment. Virus Research 13:245–262
     [Google Scholar]
  17. Laal S., Burda S., Gorny M. K., Karwowska S., Buchbinder A., Zolla-Pazner S. 1994; Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. Journal of Virology 68:4001–4008
     [Google Scholar]
  18. Laman J. D., Schellens M. M., Abacioglu Y. H., Lewis G. K., Tersmette M., Fouchier R. A. M., Langedijk J. P. M., Claassen E., Boersma W. J. A. 1992; Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gpl20 third variable domain. Journal of Virology 66:1823–831
     [Google Scholar]
  19. Levi M., Sallberg M., Ruden U., Herlyn D., Maruyama H., Wigzell H., Marks J., Wahren B. 1993; A complementarity-determining region synthetic peptide acts as a mini-antibody and neutralizes human immunodeficiency virus type 1 in vitro . Proceedings of the National Academy of Sciences, USA 90:4375–4378
     [Google Scholar]
  20. McDougal J. S., Nicholson J. K. A., Cross G. D., Cort S. P., Kennedy M. S., Mawle A. C. 1986; Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry. Journal of Immunology 137:2937–2944
     [Google Scholar]
  21. McKeating J. A., Cordell J. A., Dean C. J., Balfe P. 1992a; Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type 1 gp120. Virology 191:732–742
     [Google Scholar]
  22. McKeating J. A., Moore J. P., Ferguson M., Marsden H. S., Graham S., Almond J. W., Evans D. J., Weiss R. A. 1992b; Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS Research and Human Retroviruses 8:451–459
     [Google Scholar]
  23. McKeating J. A., Shotton C., Cordell J., Graham S., Balfe P., Sullivan N., Charles M., Page M., Bolmstedt A., Olofsson S., Kayman C., Wu Z., Pinter A., Dean C., Sodrowski J., Weiss R. A. 1993; Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. Journal of Virology 67:4932–4944
     [Google Scholar]
  24. McLain L., Dimmock N. J. 1994; Single- and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. Journal of General Virology 75:1457–1460
     [Google Scholar]
  25. McLain L., Dimmock N. J. 1996; A human CD4+ T cell line expresses functional CD64 (FcyRI), CD32 (FcyRII), and CD16 (FcyRIII) receptors, but thes> e do not enhance the infectivity of HIV-1–IgG complexes. Immunology (in press)
    [Google Scholar]
  26. McLain L., Durrani Z., Wisniewski L. A., Porta C., Lomonossoff G. P., Dimmock N. J. 1996; Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22-mer amino acid peptide expressed on the surface of a plant virus. Vaccine 14:799–810
     [Google Scholar]
  27. Maddon P. J., Dalgleish A. G., McDougall J. S., Clapham P. R., Weiss R. A., Axel R. 1986; The T4 receptor encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47:333–348
     [Google Scholar]
  28. Marsh M., Pelchen-Matthews A. 1993; Entry of animal viruses into cells. Reviews in Medical Virology 3:173–185
     [Google Scholar]
  29. Moore J. P., Ho D. D. 1995; HIV-1 neutralization: the consequences of viral adaption to growth on transformed T cells. AIDS 9: (Suppl. A) S117–S136
     [Google Scholar]
  30. Moore J. P., Klasse P. J. 1992; Thermodynamic and kinetic analysis of sCD4 binding to HIV-1 virions and gp120 dissociation. AIDS Research and Human Retroviruses 8:443–450
     [Google Scholar]
  31. Moore J. P., Nara P. L. 1991; The role of the V3 loop of gpl20 in HIV infection. AIDS 5: (Suppl. 2) S21–S33
     [Google Scholar]
  32. Moore J. P., Jameson B. A., Weiss R. A., Sattentau Q. 1993; The HIV-cell fusion reaction. In Viral Fusion Mechanisms pp 233–289 Edited by Bentz J. Boca Raton, Fla: CRC Press;
     [Google Scholar]
  33. Moore J. P., Trkola A., Korber B., Boots L. J., Kessler J. A. II, McCutchan F. E., Mascola J. R., Ho D. D., Robinson J., Conley A. J. 1995; A human monoclonal antibody to a complex epitope in the V3 region of gp!20 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. Journal of Virology 69:122–130
     [Google Scholar]
  34. Muster T., Steindi F., Purtscher M., Trkola A., Klima A., Himmler G., Riiker F., Katinger H. 1993; A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. Journal of Virology 67:6642–6647
     [Google Scholar]
  35. Outlaw M. C., Dimmock N. J. 1993; IgG-neutralization of type A influenza viruses and the inhibition of the endosomal fusion stage of the infectious pathway. Virology 195:413–421
     [Google Scholar]
  36. Page K. A., Stearns S. M., Littman D. R. 1992; Analysis of mutations in the V3 domain of gpl60 that affect fusion and infectivity. Journal of Virology 66:524–533
     [Google Scholar]
  37. Poignard P., Klasse P. J., Sattentau Q. J. 1996; Antibody neutralization of HIV-1. Immunology Today 17:239–246
     [Google Scholar]
  38. Posner M. R., Hideshima T., Cannon T., Mukherjee M., Mayer K. H., Byrn R. A. 1991; An IgG human monoclonal antibody that reacts with HlV-l/gpl20, inhibits virus binding to cells, and neutralizes infection. Journal of Immunology 146:4325–4332
     [Google Scholar]
  39. Potts B. J., Field K. G., Wu Y. M., Posner M., Cavacini L., White-Scharf M. 1993; Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3 directed monoclonal antibodies. Virology 197:415–419
     [Google Scholar]
  40. Rigg R. J., Carver A. S., Dimmock N. J. 1989; IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo . Journal of General Virology 70:2097–2109
     [Google Scholar]
  41. Rusche J. R., Javaherian K., McDanal C., Petro J., Lynn D. L., Grimaila R., Langlois A. G., Gallo R. C., Arthur L. O., Fischinger P. J., Bolognesi D. P., Putney S. D., Matthews T. J. 1988; Antibodies that inhibit fusion of HIV-infected cells bind to a 24 amino acid sequence of the viral envelope protein, gp120. Proceedings of the National Academy of Sciences, USA 85:3198–3202
     [Google Scholar]
  42. Sattentau Q. J. 1996; Neutralization of HIV-1 by antibody. Current Opinion in Immunology 8:540–545
     [Google Scholar]
  43. Sattentau Q. J., Moore J. P. 1995; Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. Journal of Experimental Medicine 182:185–196
     [Google Scholar]
  44. Schlesinger J., Ulrich A. 1992; Growth factor signaling by receptor tyrosine kinases. Neuron 9:267–269
     [Google Scholar]
  45. Schultz T. F., Reeves J. D., Hoad J. G., Tailor C., Stephens P., Clements G., Ortlepp S., Page K. A., Moore J. P., Weiss R. A. 1993; Effect of mutations in the V3 loop of HIV-gpl20 on infection and susceptibility to proteolytic cleavage. AIDS Research and Human Retroviruses 9:159–166
     [Google Scholar]
  46. Skinner M. A., Langlois A. J., McDanal C. B., McDougal J. S., Bolognesi D. P., Matthews T. J. 1988; Neutralizing antibodies to an immunodominant envelope sequence do not prevent gpl20 binding to CD4. Journal of Virology 62:4195–4200
     [Google Scholar]
  47. Smith T. J., Olson N. H., Cheng R. H., Liu H., Chase E. S., Lee W. M., Leippe D. M., Mosser A. G., Rueekert R. R., Baker T. S. 1993; Structure of human rhinovirus complexed with Fab fragments from a neutralizing antibody. Journal of Virology 67:1148–1158
     [Google Scholar]
  48. Sun N.-C., Ho D. D., Sun C. R. Y., Liou R.-S., Gordon W., Fung M. S. C., Li X.-L., Ting R. C., Lee T.-H., Chang N. T., Chang T.-W. 1989; Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. Journal of Virology 63:3579–3585
     [Google Scholar]
  49. Tilley S. A., Honnen W. J., Racho M. E., Chou T.-C., Pinter A. 1992; Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gpl20. AIDS Research and Human Retroviruses 8:461–467
     [Google Scholar]
  50. White-Seharf M. E., Potts B. J., Smith L. M., Sokolowski K. A., Rusche J. R., Silver S. 1993; Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192:197–206
     [Google Scholar]
  51. Wilson M., Reitz M. S., Aldrich K., Klasse P. J., Blomberg J., Gallo R. C., Robert-Guroff M. 1990; The site of an immune-selected point mutation in the transmembrane protein of the human immunodeficiency virus type 1 does not constitute the neutralization epitope. Journal of Virology 64:3240–3248
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-77-12-2931
Loading
Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1
J. Gen. Virol. 77, 2931 (1996); https://doi.org/10.1099/0022-1317-77-12-2931
/content/journal/jgv/10.1099/0022-1317-77-12-2931
/content/journal/jgv/10.1099/0022-1317-77-12-2931
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error